Literature DB >> 26402005

Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.

Jeriel Thomas-Richard Keeney1, Shaher Ibrahimi1, Liqin Zhao1,2.   

Abstract

Three major genetic isoforms of apolipoprotein E (ApoE), ApoE2, ApoE3, and ApoE4, exist in humans and lead to differences in susceptibility to Alzheimer's disease (AD). This study investigated the impact of human ApoE isoforms on brain metabolic pathways involved in glucose utilization and amyloid-β (Aβ) degradation, two major areas that are significantly perturbed in preclinical AD. Hippocampal RNA samples from middle-aged female mice with targeted human ApoE2, ApoE3, and ApoE4 gene replacement were comparatively analyzed with a qRT-PCR custom array for the expression of 85 genes involved in insulin/insulin-like growth factor (Igf) signaling. Consistent with its protective role against AD, ApoE2 brain exhibited the most metabolically robust profile among the three ApoE genotypes. When compared to ApoE2 brain, both ApoE3 and ApoE4 brains exhibited markedly reduced levels of Igf1, insulin receptor substrates (Irs), and facilitated glucose transporter 4 (Glut4), indicating reduced glucose uptake. Additionally, ApoE4 brain exhibited significantly decreased Pparg and insulin-degrading enzyme (Ide), indicating further compromised glucose metabolism and Aβ dysregulation associated with ApoE4. Protein analysis showed significantly decreased Igf1, Irs, and Glut4 in ApoE3 brain, and Igf1, Irs, Glut4, Pparg, and Ide in ApoE4 brain compared to ApoE2 brain. These data provide the first documented evidence that human ApoE isoforms differentially affect brain insulin/Igf signaling and downstream glucose and amyloid metabolic pathways, illustrating a potential mechanism for their differential risk in AD. A therapeutic strategy that enhances brain insulin/Igf1 signaling activity to a more robust ApoE2-like phenotype favoring both energy production and amyloid homeostasis holds promise for AD prevention and early intervention.

Entities:  

Keywords:  Alzheimer’s disease; apolipoprotein E2; apolipoprotein E3; apolipoprotein E4; early intervention; glucose metabolism; glucose transporter 4; insulin-degrading enzyme; insulin-like growth factor 1; peroxisome proliferator-activated receptor gamma

Mesh:

Substances:

Year:  2015        PMID: 26402005      PMCID: PMC5485924          DOI: 10.3233/JAD-150348

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  99 in total

Review 1.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

Review 2.  A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake.

Authors:  S A Summers; M J Birnbaum
Journal:  Biochem Soc Trans       Date:  1997-08       Impact factor: 5.407

3.  Ancient divergence of insulin and insulin-like growth factor.

Authors:  J E McRory; N M Sherwood
Journal:  DNA Cell Biol       Date:  1997-08       Impact factor: 3.311

Review 4.  Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus.

Authors:  Rizwanul Haque; Aamir Nazir
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

5.  Midlife income, occupation, APOE status, and dementia: a population-based study.

Authors:  T Anttila; E-L Helkala; M Kivipelto; M Hallikainen; K Alhainen; H Heinonen; A Mannermaa; J Tuomilehto; H Soininen; A Nissinen
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

6.  Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus.

Authors:  M A Aberg; N D Aberg; H Hedbäcker; J Oscarsson; P S Eriksson
Journal:  J Neurosci       Date:  2000-04-15       Impact factor: 6.167

7.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

8.  Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex.

Authors:  C Qiu; M Kivipelto; H Agüero-Torres; B Winblad; L Fratiglioni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

9.  Type 1 insulin-like growth factor receptor signaling is essential for the development of the hippocampal formation and dentate gyrus.

Authors:  Wen Liu; Ping Ye; John R O'Kusky; A Joseph D'Ercole
Journal:  J Neurosci Res       Date:  2009-10       Impact factor: 4.164

10.  Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling.

Authors:  Sunita Sharma; Jaya Prasanthi R P; Eric Schommer; Gwen Feist; Othman Ghribi
Journal:  Neurobiol Dis       Date:  2008-08-16       Impact factor: 5.996

View more
  30 in total

1.  Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer's disease.

Authors:  Roger J Mullins; Maja Mustapic; Edward J Goetzl; Dimitrios Kapogiannis
Journal:  Hum Brain Mapp       Date:  2017-01-20       Impact factor: 5.038

2.  Gene- Gene Interaction between PPARG and APOE Gene on Late-Onset Alzheimer's Disease: A Case- Control Study in Chinese Han Population.

Authors:  S Wang; L Guan; D Luo; J Liu; H Lin; X Li; X Liu
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

3.  Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study.

Authors:  Xinghu Qin; Hong You; Fang Cao; Yue Wu; Jianhua Peng; Jinwei Pang; Hong Xu; Yue Chen; Ligang Chen; Michael P Vitek; Fengqiao Li; Xiaochuan Sun; Yong Jiang
Journal:  J Neurotrauma       Date:  2016-09-27       Impact factor: 5.269

Review 4.  Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism.

Authors:  Sukhee Cho; Hyein Lee; Jinsoo Seo
Journal:  Mol Neurobiol       Date:  2021-01-21       Impact factor: 5.590

5.  Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.

Authors:  Sarah K Woody; Helen Zhou; Shaher Ibrahimi; Yafeng Dong; Liqin Zhao
Journal:  J Alzheimers Dis       Date:  2016-06-18       Impact factor: 4.472

Review 6.  Beyond the CNS: The many peripheral roles of APOE.

Authors:  Ana B Martínez-Martínez; Elena Torres-Perez; Nicholas Devanney; Raquel Del Moral; Lance A Johnson; Jose M Arbones-Mainar
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

7.  Peripheral versus Central Index of Metabolic Dysfunction and Associations with Clinical and Pathological Outcomes in Alzheimer's Disease.

Authors:  Kelsey E McLimans; Joseph L Webb; Vellareddy Anantharam; Anumantha Kanthasamy; Auriel A Willette
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention.

Authors:  Long Wu; Xin Zhang; Liqin Zhao
Journal:  J Neurosci       Date:  2018-07-02       Impact factor: 6.167

9.  Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene.

Authors:  Marie-Thérèse Traversy; Milène Vandal; Cyntia Tremblay; Marine Tournissac; Ariane Giguère-Rancourt; A David Bennett; Frédéric Calon
Journal:  Psychoneuroendocrinology       Date:  2016-11-30       Impact factor: 4.693

Review 10.  Glucose metabolic crosstalk and regulation in brain function and diseases.

Authors:  Shuai Zhang; Brittany Bolduc Lachance; Mark P Mattson; Xiaofeng Jia
Journal:  Prog Neurobiol       Date:  2021-06-10       Impact factor: 10.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.